

Docket No. 6267.N
Serial No. 09/836,804

P. 2


Amendments to the Claims

This listing of claims replaces all previous listings.

Claims 1 - 6 (cancelled)

Claim 7. (Currently Amended)

A method of treating osteoporosis or bone resorption in a vertebrate mammal in need thereof comprising the administering to the vertebrate mammal an effective amount of a compound of formula:



wherein Z_1 is $-O_2S$, $-O$, $-N(R^{107})$, $-OS$, or $-S$;

w is 0, 1, 2, or 3;

R^{23} and R^{24} are the same or different and can be H or F; and

R^1 is H, NH_2 , $NH(alkyl)C_1-C_4$, $N(alkyl)C_1-C_4$, ~~$N(alkyl)C_1-C_4$~~

$alkylC_1-C_4$; $OalkylC_1-C_4$; $SalkylC_1-C_4$; $alkylC_1-C_4$ substituted with 1-3F, 1-2Cl, CN, or $-COOalkylC_1-C_4$, or $cycloalkylC_3-C_6$, wherein in each occurrence of the alkyl group may be straight or branched; and R^{107} is

- $R^{102}O-C(R^{110})(R^{111})-C(O)-$,
- $R^{102}O-C(O)-$,
- $R^{102}-C(O)-$,
- $R^{102}-SO_2-$,
- $NC-CH_2-$,
- $FCHCH_2-$, or
- $R^{150}R^{151}NSO_2-$

wherein R^{102} is H, CH_3- , phenyl- CH_2- , or $CH_2C(O)$; each of R^{110} and R^{111} is selected from H or CH_3 ; R^{103} is $alkylC_1-C_3$ or phenyl; R^{108} is H, $alkylC_1-C_4$, $aryl(CH_2)_{0-5}$, $CNCH_2-$, $ClCH_2-$, CH_2HC- , FH_2C- , F_2HC- , or $cycloalkylC_3-C_6$; R^{150} and R^{151} are the same or different and are selected from H, $alkylC_1-C_4$, or R^{150} and R^{151} taken together with the nitrogen to which each is attached forms a monocyclic heterocyclic ring having from 3 to 6 carbon atoms.

see
10/26/04

Docket No. 6267.N
Serial No. 09/836,804
P. 3

Claim 8. (Original) The method according to claim 7 wherein said mammal is a human.

Claim 9. (Original) The method according to claim 7 wherein the compound is administered in the range of about 0.1 to about 100 mg/kg of mammal body weight/day.

Claim 10. (Original) The method according the claim 7 wherein the compound is administered orally, nasally, parenterally, topically, transdermally, or rectally.

Claim 11. (currently amended) The method according to claim 7 wherein said compound is selected from the group consisting of:

(S)-trans-[[3-[3-Fluoro-4-(tetrahydro-1-oxide-2H-thiopyran-4-yl)phenyl]-2-oxo-5-oxazolidinyl]methyl]thiourea; and

(S)-trans-[[3-[3-Fluoro-4-(4-thiomorpholinyl)phenyl]-2-oxo-5-oxazolidinyl]methyl]thioacetamide, thiomorpholine S-oxide; and

pharmaceutically acceptable salts thereof.

Claim 12. (Previously Presented) The method according to claim 7 wherein said mammal is not suffering from an bacterial infection.

Claim 13. (Cancelled)